Asian Scientist (Feb. 24, 2014) – Jubilant Biosys Ltd., an India-based provider of integrated drug discovery solutions to the global pharmaceutical industry, has expanded its drug discovery alliance with Belgium’s Janssen Pharmaceutica N.V.
The alliance, forged initially in 2011, has the aim of delivering preclinical drug candidates to Janssen for potential development and commercialization. The new agreement expands the alliance into multiple therapeutic areas.
In addition to research funding, Jubilant will also receive royalties should Janssen successfully bring the drug candidatess into clinical development and commercialization.
“We are pleased to announce the expansion of the Janssen-Jubilant collaboration and look forward to discovering novel chemical entities that address the unmet medical needs in these important disease areas,” said Dr. Subir K. Basak, President, Jubilant Biosys (Global Drug Discovery Services).
——
Source: Jubilant Biosys.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
